# Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

> **NCT05739123** · — · RECRUITING · sponsor: **Sumitomo Pharma Switzerland GmbH** · enrollment: 728 (estimated)

## Conditions studied

- Pregnancy Related
- Pregnancy Complications
- Pregnancy, High Risk

## Interventions

- **DRUG:** Relugolix-Containing Product

## Key facts

- **NCT ID:** NCT05739123
- **Lead sponsor:** Sumitomo Pharma Switzerland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2033-05
- **Final completion:** 2033-05
- **Target enrollment:** 728 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739123, "Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05739123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*